Sign in

    Avadel Pharmaceuticals PLC (AVDL)

    You might also like

    Avadel Pharmaceuticals plc is a biopharmaceutical company headquartered in Dublin, Ireland, with operations in the United States. The company specializes in developing and commercializing innovative medicines for chronic conditions. Its primary product is LUMRYZ, an extended-release formulation of sodium oxybate, designed for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

    1. LUMRYZ - Provides a once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Approved by the FDA in May 2023, it is the company's sole commercialized product and benefits from Orphan Drug Exclusivity until May 2030.
    NamePositionExternal RolesShort Bio

    Gregory J. Divis

    ExecutiveBoard

    Chief Executive Officer and Director

    None

    Gregory J. Divis joined Avadel in January 2017, became COO in March 2018, and CEO in June 2019. He has over 25 years of pharmaceutical industry experience.

    View Report →

    Jerad G. Seurer

    Executive

    General Counsel and Corporate Secretary

    None

    Jerad G. Seurer joined Avadel in October 2017 and became General Counsel in September 2020.

    Richard J. Kim

    Executive

    Chief Commercial Officer

    None

    Richard J. Kim joined Avadel in February 2021, overseeing commercial strategy and execution.

    Thomas S. McHugh

    Executive

    Chief Financial Officer

    None

    Thomas S. McHugh has been CFO since December 2019, overseeing financial operations and compliance.

    Geoffrey M. Glass

    Board

    Chair of the Board of Directors

    CEO of Kiniciti, LLC; Chairman of Ncardia and Abzena; Operating Partner at LongueVue Capital

    Geoffrey M. Glass joined the Board in July 2018 and became Chair in December 2018. He has extensive management and financial expertise.

    Linda S. Palczuk

    Board

    Director

    None

    Linda S. Palczuk has been a director since July 2018, with extensive pharmaceutical management experience.

    Mark A. McCamish, M.D., Ph.D.

    Board

    Director

    CEO of IconOVir Bio, Inc.; Board Member at Rafael Holdings, Inc. and Shasqi Pharma, Inc.

    Dr. McCamish has been a director since December 2019, with over 30 years of experience in life sciences.

    Naseem S. Amin, M.D.

    Board

    Director

    CEO of Orphalan SA; Chairman of Arix Bioscience plc; Advisory Board Member at Imperial College; Chairman of OPEN-London

    Dr. Amin joined the Board in May 2024, bringing 30 years of industry experience.

    Peter J. Thornton

    Board

    Director

    President and CFO of Envetec Sustainable Technologies Limited; Non-Executive Director of Oculer Limited

    Peter J. Thornton has been a director since June 2017, with financial expertise and corporate governance experience.

    1. With the shift towards new to oxybate patients leading to lower persistency rates and potential impacts on net patient adds, how do you plan to address this challenge and improve persistency among these patients?
    2. Given the anticipated seasonality impacts and higher gross-to-net deductions in Q4, how might these factors affect your financial performance, and what strategies are in place to mitigate them?
    3. Considering the ongoing patent litigation with Jazz Pharmaceuticals and the potential financial implications of royalty adjustments, how are you preparing for these outcomes, and can you provide an update on the status of post-trial motions and royalty rate discussions?
    4. As competitors continue to grow their patient base in the narcolepsy setting and with the potential entry of orexin agonists, how do you plan to maintain and strengthen LUMRYZ's market position, particularly among narcolepsy type 2 patients?
    5. Despite consistent patient growth, you mentioned that new to oxybate patients require more support due to lower persistency; what specific investments and strategies are you implementing to enhance patient support and ensure long-term adherence?
    CustomerRelationshipSegmentDetails

    Caremark LLC

    Specialty Pharmacy

    All

    53% of 2024 AR ($18.07M) , 44% of 2024 revenue ($74.41M)

    Accredo Health Group, Inc.

    Specialty Pharmacy

    All

    25% of 2024 AR ($8.52M) , 37% of 2024 revenue ($62.57M)

    Optum Frontier Therapies LLC

    Specialty Pharmacy

    All

    22% of 2024 AR ($7.50M) , 19% of 2024 revenue ($32.13M)

    Recent developments and announcements about AVDL.

    Earnings

    • New Earnings (Q4 2024)

      ·
      Mar 3, 2025, 4:17 PM

      Avadel’s LUMRYZ shows strong momentum as expanded sales (+15%) and 200+ new prescribers fuel growth. 2025 revenue guidance of $240M–$260M signals nearly 50% YoY gain. While Q1 may see a dip from gross-to-net headwinds, management remains confident in achieving targets.

      View full earnings summary →

    8-K Filings

    • 8-K Filing

      ·
      6 days ago
      Other Events

      On March 5, 2025, the Compensation Committee approved performance-based equity grants. The CEO received 310,000 options and 52,000 restricted shares, the CFO 72,000 options and 12,600 restricted shares, and General Counsel 84,000 options and 14,700 restricted shares. Vesting is tied to specific Nasdaq price thresholds (e.g., $11 trigger).

      View full 8-K filing →